Agencies, 08 August: Indian Council of Medical Research (ICMR) para study te janaishe. Covaxin aro Covishield vaccines mela para phal safety results debole paribo koise. Etu study results aha toh duniya te vaccine doses laga mixing te research kora otha samai te ase.
Denmark’s State Serum Institute para agae te AstraZeneca COVID-19 vaccine logote mRNA vaccines laga second dose Moderna nahoile Pfizer-BioNTech’s vaccines mela para ‘good protection’ offer kori koise.
Study samai te, ICMR para Covaxin nahoile Covishield lowa khan laga safety aro immunogenicity profile te compare korise aro phal results dekhaise.
Study lowa toh Uttar Pradesh te individuals kon first dose toh Covishield loise aro second toh six hapta bechite Covaxin loise etu opor te thakise.
Head of Epidemiology and Communicable Diseases, ICMR, Dr Samiran Panda para etu toh ekta natural experiment nesana thakise koile kelay koile individuals khan para second par toh carelessly alak doses lowa nemite.
ICMR para etu study lobole fesla kora toh manu khan dawai opor te monchinda nahoile hesitancy nahobo nemite ase koise.
Medical council para individuals laga samples jama korise koise.
Results:
Heterologous group te sob melikena 18 participants thakise aro etu lag ate tuita participants toh monchor howa nai aro hisha lowa nai koise.
Tusara khan te, 11 moda aro seven maike participants toh median age of 62 sal thakise koise. Hypertension toh ekta manu ke khobor howa thakise koise.
Sob melikena 40 individuals ke toh both homologous groups te mela thakise koise.
Etu manu khan laga safety aro immunogenicity profile toh Covishield nahoile Covaxin lowa khan ke compare korise koise.
Sob tinta groups te immunization bechite lower adverse events para combination vaccine regime laga safety te highlight korise koise.
Alpha, Beta, aro Delta variants kelaaf vaccine immunity toh heterologous group te gara thakise koise.
Hisha lowa khan laga IgG antibody aro neutralising antibody response toh homologous group para besi thakise koise.
Add Comment